Kimberly Westrich, MA, of the National Pharmaceutical Council, addresses the benefits of incorporating patient-centricity throughout the health care system to foster more accurate and better quality of care.
Kimberly Westrich, MA, of the National Pharmaceutical Council (NPC), discusses actively integrating the patient voice to create a more responsive health care system. Westrich delivered a session at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, "Innovative Approaches to Integrating the Patient Experience," where she highlighted the benefits patients have when their quality of care is considered.
At NPC, Westrich is the chief strategy officer, a role through which she offers guidance in policy research and communications. She has been a part of several research initiatives across NPC's portfolio, most significantly employer-sponsored insurance. Westrich addresses both managed care settings and pharmaceutical research to explain the importance of patient-centricity within practices.
Transcript
How can we ensure that patient-centricity remains at the core of all decision-making processes, from drug development to patient care delivery?
When we're thinking about making sure that patient-centricity is remaining at the core of the decision-making processes, I think there's 3 things that we need to do. The first thing is to define what good patient engagement looks like and then the second thing is recognizing where we are in terms of achieving that patient-centricity. The third thing is continuing to make improvement.
So starting with that first thing, what does good patient engagement look like? I like to use IAD as the acronym, which is the airport that's by my house, so IAD. "I" is interaction. Good patient engagement is an interaction between the patient and the researcher, between the patient and the decision-maker. It's not something that is done to the patient, it's something that's done with the patient. That's the "I."
The "A" is "At all stages." You don't want to just bring the patient in at the end of a research project or at the end of the decision-making. Ideal patient engagement has the patient involved throughout the process. Then the final part, "D," that is decision-making that is guided by the input and the expertise of the patient. It's not just we're going to bring the patient in, we're going to get some context from them, and that will just be framing to the decision, but it actually guides the decision. So that's what good patient engagement looks like, IAD: interaction, all stages, decision-making that's guided.
Now, if you think about actually achieving that, you can imagine a spectrum and on one end of the spectrum, you have absolutely no engagement with the patient, and at the other end, you've got full engagement with patient communities. You've got that interaction, you've got them involved at all stages, and their input is actually guiding decision making. Now that perfect engagement is actually really hard to achieve and we don't want to let perfect be the enemy of the good.
So, to ensure that patient engagement is something that is happening at all stages of these decisions, we need to think about where are we on the spectrum and how do we keep moving toward that fuller engagement that's more impactful of the decisions where patients are cocreators. This can be in all sorts of decisions across the lifecycle, from patient-focused drug development, from health technology assessments that are looking at the value of the drug, to care decisions, formulary decision-makings. What we want to do is think about what good patient engagement looks like, where are we on the spectrum of achieving good patient engagement, and then what little steps can we take to keep moving toward greater and greater patient engagement.
Building Accountability Into GLP-1 Benefit Design: Lessons From Delaware and Philadelphia
August 20th 2025Employers explore glucagon-like peptide-1 (GLP-1) therapies' impact on health benefits, showcasing accountability and data-driven strategies in Philadelphia, Pennsylvania, and Wilmington, Delaware, for sustainable health programs.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More